CNSP

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CNS Pharmaceuticals Inc revenue for the last quarter amounts to -3.25M USD, decreased -42.20 % YoY.

CNS Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased % YoY.

CNS Pharmaceuticals Inc (CNSP) has 4 emplpoyees as of December 15 2025.

Today CNSP has the market capitalization of 4.83M USD.